The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

Founded Year

2002

Stage

Series A | Alive

Total Raised

$5M

Last Raised

$5M | 19 yrs ago

About Ansata Therapeutics

Founded in early 2002 by Avalon Ventures and Domain Associates, Ansata Therapeutics is developing & commercializing novel medicines that capitalize on the Company's industry- leading expertise and intellectual property in molecular transduction. Ansata has several preclinical programs under development in the oncology and neurodegenerative disease areas. The company strives to rapidly advance lead compounds from late-stage preclinical research into clinical development by leveraging its proprietary knowledge of common dermatological diseases.

Ansata Therapeutics Headquarter Location

505 Coast Boulevard South

La Jolla, California, 92037,

United States

858-754-3000

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Ansata Therapeutics

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Ansata Therapeutics is included in 2 Expert Collections, including Cancer.

C

Cancer

1,179 items

Pharmaceutical and biotechnology companies with cancer therapy drug candidates.

B

Biopharma Tech

5,241 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

  • When was Ansata Therapeutics founded?

    Ansata Therapeutics was founded in 2002.

  • Where is Ansata Therapeutics's headquarters?

    Ansata Therapeutics's headquarters is located at 505 Coast Boulevard South, La Jolla.

  • What is Ansata Therapeutics's latest funding round?

    Ansata Therapeutics's latest funding round is Series A.

  • How much did Ansata Therapeutics raise?

    Ansata Therapeutics raised a total of $5M.

  • Who are the investors of Ansata Therapeutics?

    Investors of Ansata Therapeutics include Avalon Ventures and Domain Associates.

  • Who are Ansata Therapeutics's competitors?

    Competitors of Ansata Therapeutics include Asuragen, Kereos, Acorda Therapeutics, Molecular Templates, Clovis Oncology and 16 more.

You May Also Like

N
NeuroMolecular Pharmaceuticals

NeuroMolecular Pharmaceuticals is developing and commercializing superior neuroprotective medicines for the treatment of central nervous system (CNS) disorders. The Company has built a robust pipeline of neuropsychiatric products based upon its scientists' unique understanding of glutamate's central role in mediating CNS disorders. NeuroMolecular is rapidly advancing its next-generation medicines into clinical studies, with preclinical programs underway in depression, pain, Alzheimer's disease, Parkinson's disease, multiple sclerosis and epilepsy. NeuroMolecular is initially focusing on the development of superior derivatives and dosage formulations of memantine, a drug recently approved by the U.S. Food and Drug Administration (FDA) for the treatment of Alzheimer's disease.

Q
Q Therapeutics

Q Therapeutics, Inc. is developing glial cell-based therapeutic products for central nervous system disorders in which a disease or injury inhibits normal myelin growth and enzyme performance.

I
Intarcia Therapeutics

Intarcia Therapeutics is a biopharmaceutical company based in Boston, Massachusetts. Intarcia is engaged in the development of a pipeline of products for the proprietary Medici Drug Delivery System comprised of three technologies: A stabilization technology that allows for proteins, peptides, antibody fragments, and other highly potent small molecules to be stabilized at or above human body temperatures, a matchstick-sized osmotic mini-pump that is placed under the dermal layer of skin to deliver a continuous and consistent flow of medication, and a placement technology including proprietary tools designed to provide an optimal user experience.

A
Ascent Therapeutics

Ascent Therapeutics is a biopharmaceutical company developing a approach to the treatment of human disease that rapidly generates pharmaceuticals critical to many disease processes.

S
Synapsin Pharmaceuticals

SYNAPSIN is developing therapeutic strategies for the treatmentand prevention ofneurodegenerative disorders such as Alzheimer's disease (AD),Parkinson's disease, Amyotrophic Lateral Sclerosis (ALS), and spinal cord injury.

N
Neuraltus Pharmaceuticals

Neuraltus Pharmaceuticals is a privately-held biopharmaceutical company dedicated to developing and commercializing innovative therapeutics that address critical unmet needs for patients and physicians in the treatment of neurodegenerative diseases. The Company is collaborating with global ALS specialists and seeking input from patient advocacy organizations to help inform the clinical development path and better understand the needs of people affected by the disease.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.